

Short Communication

Simultaneous expression of COX-2 and mPGES-1 in mouse gastrointestinal hamartomas

H Takeda¹, H Miyoshi¹, Y Tamai², M Oshima¹ and MM Taketo^{*,1}

¹Department of Pharmacology, Kyoto University Graduate School of Medicine, Kyoto 606-8501, Japan; ²Banyu Tsukuba Research Institute, Tsukuba 300-2611, Japan

Cyclo-oxygenase (COX)-2 is induced in various types of cancer tissues. Here, we demonstrate stromal expression of both COX-2 and microsomal prostaglandin E₂ synthase (mPGES)-1 in gastrointestinal hamartomas developed in *Lkb1*^{+/-}, *Smad4*^{+/-} and *Cdx2*^{+/-} mice. These results suggest that PGE₂ produced by COX-2 and mPGES-1 plays an important role in hamartoma development regardless of the mutated genes causing hamartomas.

British Journal of Cancer (2004) 90, 701–704. doi:10.1038/sj.bjc.6601584 www.bjcancer.com

© 2004 Cancer Research UK

Keywords: hamartoma; *LKB1*; *SMAD4*; *CDX2*; COX-2; mPGES-1

Using *Apc*^{A716} mouse mutant, a model for familial adenomatous polyposis (FAP), we demonstrated earlier that disruption of the gene encoding cyclo-oxygenase (COX)-2 or prostaglandin E₂ (PGE₂) receptor EP2 suppresses intestinal polyposis (Oshima *et al*, 1996; Sonoshita *et al*, 2001). These results indicate that PGE₂ produced through the COX-2 pathway plays an important role in intestinal tumorigenesis. One of the PGE₂ synthases, microsomal prostaglandin E₂ synthase (mPGES)-1 appears to be responsible for PGE₂ production in tumour tissues, because this enzyme is induced and functionally coupled with COX-2 in a human embryonic kidney cell line (Murakami *et al*, 2000). Likewise, COX-2 and mPGES-1 are induced simultaneously in human colorectal cancer tissues (Yoshimatsu *et al*, 2001), intestinal-type gastric adenocarcinomas (Van Rees *et al*, 2003) and *Apc*^{A716} mouse intestinal adenomas (Takeda *et al*, 2003).

Peutz–Jeghers syndrome (PJS) and juvenile polyposis syndrome (JPS) are autosomal dominant diseases characterised by hamartomatous polyps of the gastrointestinal tract with an increased risk of cancer development. Germ line mutations in the *LKB1* (Hemminki *et al*, 1998; Jenne *et al*, 1998) and *SMAD4* (Howe *et al*, 1998) are responsible for subpopulations of PJS and JPS, respectively. Gene-targeted mice heterozygous for *Lkb1* and *Smad4* develop gastrointestinal hamartomas that have histological characteristics similar to those of PJS and JPS, respectively (Takaku *et al*, 1999; Miyoshi *et al*, 2002). Recently, it has been reported that COX-2 expression is induced in hamartomatous polyps of PJS patients and *Lkb1*^{+/-} mice (Rossi *et al*, 2002; de Leng *et al*, 2003; McGarrity *et al*, 2003), suggesting the roles of COX-2 in hamartoma development. However, COX-2 expression in other types of hamartomas has not yet been examined. Furthermore, it is important to determine whether the expression of mPGES-1 is also induced in hamartoma tissues as in intestinal adenomas and carcinomas.

Here we show that both COX-2 and mPGES-1 are induced in gastric hamartoma tissues of *Lkb1*^{+/-} and *Smad4*^{+/-} mice. In addition, we demonstrate induction of these enzymes also in *Cdx2*^{+/-} mouse colonic hamartomas. These results strongly suggest that production of PGE₂ is responsible for gastrointestinal hamartoma development as in intestinal adenomatous polyposis.

MATERIALS AND METHODS

All *in vivo* experiments were carried out with ethical committee approval and met the standards required by the UKCCCR guidelines (Workman *et al*, 1998). Constructions of *Lkb1*^{+/-}, *Smad4*^{+/-} and *Cdx2*^{+/-} mutant mice have been described previously (Takaku *et al*, 1999; Tamai *et al*, 1999; Miyoshi *et al*, 2002). We used these mouse models to examine the expression patterns of COX-1, COX-2 and mPGES-1 in hamartomas that were caused by mutations in the putative genes, *Lkb1*, *Smad4* and *Cdx2*, respectively. As the expression of COX-2 and mPGES-1 can be affected by various conditions such as infections, inflammations and host immune responses, it is important to use congenic mice bred in a specific pathogen-free (SPF) facility and compare them with the age-matched littermate controls. The results from these mouse experiments should provide important pieces of evidence applicable to human clinical research. Ages of mutant mice used in this study were 60–66, 76–90 and 20–35 weeks for *Lkb1*^{+/-}, *Smad4*^{+/-} and *Cdx2*^{+/-}, respectively. Hamartomas were sampled from seven independent mice and used for further analysis.

For immunoblotting, tissue samples were homogenised and sonicated in lysis buffer (50 mM phosphate buffer pH 7.0, 100 mM NaCl, 2 mM EDTA) containing a protease inhibitor cocktail (Roche Diagnostics, Nonnenwald, Penzberg, Germany). After centrifugation at 10 000 × g at 4°C for 10 min, 40 µg of the supernatant protein was mixed with 6 × SDS sample buffer (350 mM Tris-HCl, pH 6.8, 36% glycerol, 10% SDS, 600 mM DTT), separated in SDS–polyacrylamide gels and transferred onto PVDF membranes. After blocking with 5% skimmed milk/Tris-buffered saline/Tween 20,

*Correspondence: MIM Taketo; E-mail: taketo@mfour.med.kyoto-u.ac.jp
Received 20 October 2003; revised 20 November 2003; accepted 20 November 2003

membranes were incubated with an antibody for COX-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), COX-2, cPGES or mPGES-1 (Cayman Chemical, Ann Arbor, MI, USA) at 1000-fold dilution, or for β -actin (Sigma) at 5000-fold dilution. The ECL detection system (Amersham Pharmacia, Uppsala, Sweden) was used to detect the signals.

For immunohistochemistry, tissue samples were fixed in 4% paraformaldehyde, embedded in paraffin wax and sectioned at 4 μ m. After pretreatment in 3% H₂O₂ in methanol, sections were boiled in 10 mM citrate buffer (pH 6.0) in a microwave oven for 5 min. Sections were blocked with 3% BSA-10% normal serum for 1 h and incubated with the primary antibody for COX-1, COX-2 or mPGES-1 at 400-fold dilution. Immunostaining signals were visualised using Vectastain Elite Kit (Vector Laboratories, Burlingame, CA, USA).

RESULTS AND DISCUSSION

Hamartomatous polyp tissues were excised from the stomach of *Lkb1*^{+/-} and *Smad4*^{+/-} mice and from the colon of *Cdx2*^{+/-} mice. We first examined the expression levels of COX enzymes and PGE₂ synthases in these tumour tissues by immunoblotting (Figure 1). The expression of COX-2 and mPGES-1 was detected in all hamartomatous polyps, whereas these enzymes were rarely expressed in the normal tissues. On the other hand, COX-1 and cPGES were detected in both normal and hamartoma tissues. These results are consistent with our recent report that COX-1 and cPGES are expressed constitutively in the normal mouse intestines,




Figure 1 Immunoblotting analysis of COX-1, COX-2, cPGES and mPGES-1 in the normal and polyp tissues. N, normal stomach (*Lkb1*^{+/-}, *Smad4*^{+/-}) or intestine (*Cdx2*^{+/-}); P, hamartomatous polyp.

whereas COX-2 and mPGES-1 are induced in the intestinal polyps of *Apc*^{D716} mice (Takeda *et al*, 2003).

We next determined by immunohistochemistry the localisation of COX-1, COX-2 and mPGES-1 in the hamartoma tissues of the *Lkb1*^{+/-}, *Smad4*^{+/-} and *Cdx2*^{+/-} mice, respectively (Figure 2). In




Figure 2 Immunohistochemical analysis of COX-1, COX-2 and mPGES-1 in hamartomas. Expression of COX-1 (A, D, G), COX-2 (B, E, H) and mPGES-1 (C, F, I) in hamartomatous polyps of *Lkb1*^{+/-} (A–C), *Smad4*^{+/-} (D–F) and *Cdx2*^{+/-} (G–I) mice, respectively. Bars; 50 μ m.

all samples, COX-1 was expressed in the stromal cells of hamartomas (Figure 2A, D, G) as well as in those of the normal mucosa (data not shown). Expression of COX-2 and mPGES-1 was detected in the stroma of hamartomas near the intestinal lumen, overlapping partly with the COX-1-expressing cells (Figure 2B–I). Moreover, cells expressing COX-2 and mPGES-1 appeared to be the same stromal cells showing a fibroblast-like morphology. There was no apparent difference in the expression patterns of COX-1, COX-2 and mPGES-1 among the hamartomas developing in different mutants. We did not find any difference in the expression levels and cell types among the individual mice of each model. These results indicate that COX-2 and mPGES-1 are induced in the stromal cells, and are consistent with our recent results with the intestinal adenomas in *Apc*^{A716} mice (Takeda et al, 2003). Namely, COX-2 and mPGES-1 are induced simultaneously in the COX-1-expressing stromal fibroblasts. Given that COX-2 and mPGES-1 are functionally coupled (Murakami et al, 2000), PGE₂ levels in the hamartomas should be elevated significantly by simultaneous induction of both enzymes from the basal level that is secured by the COX-1 pathway alone. Although *CDX2* mutations have not been detected in any hereditary hamartoma syndromes, it is conceivable that a subset of sporadic hamartomas contains *CDX2* mutations. Regardless of the mutated genes that caused hamartomas, stromal PGE₂ production appears to play a key role in the hamartoma expansion.

The PGE₂ signalling stimulates tumour angiogenesis through the EP2 receptor (Seno et al, 2002), increases cell survival and motility

(Sheng et al, 2001), inhibits host immune responses (Huang et al, 1998) and activates epidermal growth factor receptor (EGFR) (Pai et al, 2002). Accordingly, it is conceivable that stromal PGE₂ in the hamartomas contributes to tumour expansion through these effects.

Inhibition of COX-2 by NSAIDs or COX-2-selective inhibitors suppresses intestinal polyposis in *Apc*^{A716} mice and FAP patients (Oshima et al, 1996; Steinbach et al, 2000). In addition, administration of COX-2 inhibitor to trefoil factor 1 (TFF1)-deficient mice suppresses gastric adenomas that are caused without Wnt signalling activation (Saukkonen et al, 2003). The results suggest that COX-2 induction in the tumour stroma is independent of the molecular mechanism that initiates tumorigenesis in the epithelial cells. These results, taken together, strongly suggest that COX-2 inhibitors, and possibly EP antagonists, are therapeutic agents effective for not only adenomatous polyposis but also hamartomas of the gastrointestinal tract. As hamartomatous polyps can progress into neoplastic tumours (Wang et al, 1999), COX-2 inhibitors may also turn out to be cancer chemopreventive agents suitable for hereditary hamartoma syndromes.

ACKNOWLEDGEMENTS

This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

REFERENCES

- Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M, Hoglund P, Jarvinen H, Kristo P, Pelin K, Ridanpaa M, Salovaara R, Toro T, Bodmer W, Olschwang S, Olsen AS, Stratton MR, de la Chapelle A, Aaltonen LA (1998) A serine/threonine kinase gene defective in Peutz–Jeghers syndrome. *Nature* **391**: 184–187
- Howe JR, Roth S, Ringold JC, Summers RW, Jarvinen HJ, Siston P, Tomlinson IPM, Houlston RS, Bevan S, Mitros FA, Stone EM, Aaltonen LA (1998) Mutations in the SMAD4/DPC4 gene in juvenile polyposis. *Science* **280**: 1086–1088
- Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H, Dubinett SM (1998) Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. *Cancer Res* **58**: 1208–1216
- Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Muller O, Back W, Zimmer M (1998) Peutz–Jeghers syndrome is caused by mutations in a novel serine threonine kinase. *Nat Genet* **18**: 38–43
- de Leng WWJ, Westerman AM, Westerman MAJ, de Rooij FWM, van Dekken H, de Goeij AFPM, Gruber SB, Wilson JHP, Offerhaus GJA, Giardiello FM, Keller JJ (2003) Cyclooxygenase 2 expression and molecular alterations in Peutz–Jeghers hamartomas and carcinomas. *Clin Cancer Res* **9**: 3065–3072
- McGarrity TJ, Peiffer LP, Amos CI, Frazier ML, Ward MG, Howett MK (2003) Overexpression of cyclooxygenase 2 in hamartomatous polyps of Peutz–Jeghers syndrome. *Am J Gastroenterol* **98**: 671–678
- Miyoshi H, Nakau M, Ishikawa T, Seldin FM, Oshima M, Taketo MM (2002) Gastrointestinal hamartomatous polyposis in *Lkb1* heterozygous knockout mice. *Cancer Res* **62**: 2261–2266
- Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, Ikeda T, Fueki M, Ueno A, Oh-ishi S, Kudo I (2000) Regulation of prostaglandin E₂ biosynthesis by inducible membrane-associated prostaglandin E₂ synthase that acts in concert with cyclooxygenase-2. *J Biol Chem* **275**: 32783–32792
- Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM (1996) Suppression of intestinal polyposis in *Apc*^{A716} knockout mice by inhibition of cyclooxygenase 2 (COX-2). *Cell* **87**: 803–809
- Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS (2002) Prostaglandin E₂ transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. *Nat Med* **8**: 289–293
- Rossi DJ, Ylikorkala A, Korsisaari N, Salovaara R, Luukko K, Launonen V, Henkemeyer M, Ristimaki A, Aaltonen LA, Makela TP (2002) Induction of cyclooxygenase-2 in a mouse model of Peutz–Jeghers polyposis. *Proc Natl Acad Sci USA* **99**: 12327–12332
- Saukkonen K, Tomasetto C, Narko K, Rio M-C, Ristimaki A (2003) Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice. *Cancer Res* **63**: 3032–3036
- Seno H, Oshima M, Ishikawa T, Oshima H, Takaku K, Chiba T, Narumiya S, Taketo MM (2002) Cyclooxygenase 2- and prostaglandin E₂ receptor EP₂-dependent angiogenesis in *Apc*^{A716} mouse intestinal polyps. *Cancer Res* **62**: 506–511
- Sheng H, Shao J, Washington MK, DuBois RN (2001) Prostaglandin E₂ increases growth and motility of colorectal carcinoma cells. *J Biol Chem* **276**: 18075–18081
- Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, Oshima M, Taketo MM (2001) Acceleration of intestinal polyposis through prostaglandin receptor EP2 in *Apc*^{A716} knockout mice. *Nat Med* **7**: 1048–1051
- Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. *N Engl J Med* **342**: 1946–1952
- Takaku K, Miyoshi H, Matsunaga A, Oshima M, Sasaki N, Taketo MM (1999) Gastric and duodenal polyps in *Smad4* (*Dpc4*) knockout mice. *Cancer Res* **59**: 6113–6117
- Takeda H, Sonoshita M, Oshima H, Sugihara K, Chulada PC, Langenbach R, Oshima M, Taketo MM (2003) Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. *Cancer Res* **63**: 4872–4877
- Tamai Y, Nakajima R, Ishikawa T, Takaku K, Seldin MF, Taketo MM (1999) Colonic hamartoma development by anomalous duplication in *Cdx2* knockout mice. *Cancer Res* **59**: 2965–2970
- Van Rees BP, Sivula A, Thoren S, Yokozaki H, Jakobsson PJ, Offerhaus GA, Ristimaki A (2003) Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines. *Int J Cancer* **107**: 551–556
- Wang Z-J, Ellis I, Zauber P, Iwama T, Marchese C, Talbot I, Xue W-H, Yan Z-Y, Tomlinson I (1999) Allelic imbalance at the *LKB1* (*STK11*)

locus in tumors from patients with Peutz–Jeghers' syndrome provides evidence for a hamartoma-(adenoma)-carcinoma sequence. *J Pathol* **188**: 9–13

Workman P, Twentyman P, Balkwill F, Balman A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom Co-ordinating Committee on Cancer Research

(UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). *Br J Cancer* **77**: 1–10

Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson P-J, DeLellis RA, Subbaramaiah K, Dannenberg AJ (2001) Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. *Clin Cancer Res* **7**: 3971–3976